Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Gary Ingenito Insider Profile
11 Followers
Gary Ingenito, Chief Med. & Reg. Officer at Catalyst Pharma, holds 55.85K shares in Catalyst Pharma (Ticker: CPRX).
Gary Ingenito Catalyst Pharma (CPRX)Chief Med. & Reg. Officer
Catalyst Pharma (CPRX)
Chief Med. & Reg. Officer
Ranked #59,630 out of 99,797 Corporate Insiders
Profitable Transactions
5 out of 8 Profitable Transactions
Average Return
-4.40%
Average return per transaction
Time Frame
Compare to
Insider Roles
Chief Med. & Reg. Officer
Roles that Gary Ingenito holds in companies
Most Profitable Insider Trade
The most profitable trade made by Gary Ingenito
Gary Ingenito's Trading History
List of latest transactions for each holding click on a transaction to see Gary Ingenito's performance on stock
You May Also Like
Gary Ingenito insider profile FAQ
What is the percentage of profitable transactions made by Gary Ingenito?
The percentage of profitable transactions made by Gary Ingenito is 63%.
What is the average return per transaction made by Gary Ingenito?
The average return per transaction made by Gary Ingenito is -4.40%.
What stocks does Gary Ingenito hold?
Gary Ingenito holds: CPRX stocks.
What was Gary Ingenito’s latest transaction?
Gary Ingenito latest transaction was an Uninformative Buy of $96.92K.
What was Gary Ingenito's most profitable transaction?
Gary Ingenito’s most profitable transaction was an Informative Sell of CPRX stock on November 22, 2019. The return on the trade was 24.70%.
What is Gary Ingenito's role in Catalyst Pharma?
Gary Ingenito's role in Catalyst Pharma is Chief Med. & Reg. Officer.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.